BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 16525679)

  • 1. Synergistic growth suppression induced in esophageal squamous cell carcinoma cells by combined treatment with docetaxel and heavy carbon-ion beam irradiation.
    Kitabayashi H; Shimada H; Yamada S; Yasuda S; Kamata T; Ando K; Tsujii H; Ochiai T
    Oncol Rep; 2006 Apr; 15(4):913-8. PubMed ID: 16525679
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of carbon-ion radiotherapy combined with a novel histone deacetylase inhibitor, cyclic hydroxamic-acid-containing peptide 31 in human esophageal squamous cell carcinoma.
    Kano M; Yamada S; Hoshino I; Murakami K; Akutsu Y; Sakata H; Nishimori T; Usui A; Miyazawa Y; Kamada T; Tsujii H; Matsubara H
    Anticancer Res; 2009 Nov; 29(11):4433-8. PubMed ID: 20032389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Growth suppression of esophageal squamous cell carcinoma induced by heavy carbon-ion beams combined with p53 gene transfer.
    Oohira G; Yamada S; Ochiai T; Matsubara H; Okazumi S; Ando K; Tsujii H; Hiwasa T; Shimada H
    Int J Oncol; 2004 Sep; 25(3):563-9. PubMed ID: 15289857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparing docetaxel plus cisplatin versus fluorouracil plus cisplatin in esophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy.
    Xi M; Zhang P; Zhang L; Yang YD; Liu SL; Li Y; Fu JH; Liu MZ
    Jpn J Clin Oncol; 2017 Aug; 47(8):683-689. PubMed ID: 28453815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The suppression of aurora-A/STK15/BTAK expression enhances chemosensitivity to docetaxel in human esophageal squamous cell carcinoma.
    Tanaka E; Hashimoto Y; Ito T; Kondo K; Higashiyama M; Tsunoda S; Ortiz C; Sakai Y; Inazawa J; Shimada Y
    Clin Cancer Res; 2007 Feb; 13(4):1331-40. PubMed ID: 17317845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Antitumor effect of docetaxel against human esophagus tumor cell lines and tumor xenografts in nude mice].
    Shakuto S; Fujita F; Fujita M
    Gan To Kagaku Ryoho; 2006 Mar; 33(3):337-43. PubMed ID: 16531714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Weekly docetaxel and gemcitabine in previously treated metastatic esophageal squamous cell carcinoma.
    Lee MY; Jung KS; Kim HS; Lee JY; Lim SH; Kim M; Jung HA; Kim SM; Sun JM; Ahn MJ; Lee J; Park SH; Yi SY; Hwang IG; Lee SC; Ahn HK; Lim DH; Lee SI; Park KW
    World J Gastroenterol; 2015 Apr; 21(14):4268-74. PubMed ID: 25892878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Docetaxel and cisplatin concurrent with radiotherapy versus 5-fluorouracil and cisplatin concurrent with radiotherapy in treatment for locally advanced oesophageal squamous cell carcinoma: a randomized clinical study.
    Zhao T; Chen H; Zhang T
    Med Oncol; 2012 Dec; 29(5):3017-23. PubMed ID: 22476809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fractionated irradiation induced radio-resistant esophageal cancer EC109 cells seem to be more sensitive to chemotherapeutic drugs.
    Xie L; Song X; Yu J; Wei L; Song B; Wang X; Lv L
    J Exp Clin Cancer Res; 2009 May; 28(1):68. PubMed ID: 19470182
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Efficacy and side-effects of docetaxel combined with cisplatin on the treatment of local advanced esophageal cancer with concomitant radiation therapy].
    Zhang TR; Zhao T; Xu X; Gu XW; Pan YK
    Zhonghua Zhong Liu Za Zhi; 2010 Oct; 32(10):791-4. PubMed ID: 21163074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of docetaxel, cisplatin, and 5-fluorouracil chemotherapy for superficial esophageal squamous cell carcinoma.
    Miyawaki Y; Nakajima Y; Kawada K; Okada T; Tokairin Y; Kawano T
    Dis Esophagus; 2017 Feb; 30(2):1-8. PubMed ID: 27001629
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adenovirus-mediated FIR demonstrated TP53-independent cell-killing effect and enhanced antitumor activity of carbon-ion beams.
    Kano M; Matsushita K; Rahmutulla B; Yamada S; Shimada H; Kubo S; Hiwasa T; Matsubara H; Nomura F
    Gene Ther; 2016 Jan; 23(1):50-6. PubMed ID: 26241176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A microemulsion co-loaded with Schizandrin A-docetaxel enhances esophageal carcinoma treatment through overcoming multidrug resistance.
    Su X; Gao C; Shi F; Feng X; Liu L; Qu D; Wang C
    Drug Deliv; 2017 Nov; 24(1):10-19. PubMed ID: 28155336
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective, open, multicentre Phase I/II trial to assess safety and efficacy of neoadjuvant radiochemotherapy with docetaxel and cisplatin for esophageal carcinoma.
    Ma HB; Di ZL; Wen J; Ke Y; Sun X; Ren J
    Jpn J Clin Oncol; 2015 Feb; 45(2):169-75. PubMed ID: 25416813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Small interfering RNA targeting epidermal growth factor receptor enhances chemosensitivity to cisplatin, 5-fluorouracil and docetaxel in head and neck squamous cell carcinoma.
    Nozawa H; Tadakuma T; Ono T; Sato M; Hiroi S; Masumoto K; Sato Y
    Cancer Sci; 2006 Oct; 97(10):1115-24. PubMed ID: 16984384
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Pilot Trial of S-1 and Paclitaxel in Unresectable or Postoperative Recurrent Esophageal Squamous Cell Carcinoma Pretreated by Fluorouracil, Cisplatin, and Docetaxel Chemotherapy.
    Nakajima Y; Kawada K; Tokairin Y; Hoshino A; Okada T; Kawano T
    Dig Surg; 2018; 35(2):131-137. PubMed ID: 28554183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I Study of Docetaxel Plus Nedaplatin in Patients With Metastatic or Recurrent Esophageal Squamous Cell Carcinoma After Cisplatin Plus 5-Fluorouracil Treatment.
    Kajiura S; Hosokawa A; Yoshita H; Ueda Y; Ueda A; Mihara H; Ando T; Fujinami H; Nishikawa J; Ogawa K; Minemura M; Sugiyama T
    Am J Clin Oncol; 2016 Feb; 39(1):13-7. PubMed ID: 24322336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metformin-induced alterations in nucleotide metabolism cause 5-fluorouracil resistance but gemcitabine susceptibility in oesophageal squamous cell carcinoma.
    Mynhardt C; Damelin LH; Jivan R; Peres J; Prince S; Veale RB; Mavri-Damelin D
    J Cell Biochem; 2018 Jan; 119(1):1193-1203. PubMed ID: 28722177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of neoadjuvant chemotherapy with docetaxel, nedaplatin, and S1 for advanced esophageal squamous cell carcinoma.
    Tanaka Y; Yoshida K; Tanahashi T; Okumura N; Matsuhashi N; Yamaguchi K
    Cancer Sci; 2016 Jun; 107(6):764-72. PubMed ID: 27061001
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of biweekly docetaxel, cisplatin, and 5-fluorouracil chemotherapy for advanced esophageal squamous cell carcinoma.
    Tanaka Y; Yoshida K; Yamada A; Tanahashi T; Okumura N; Matsuhashi N; Yamaguchi K; Miyazaki T
    Cancer Chemother Pharmacol; 2016 Jun; 77(6):1143-52. PubMed ID: 26896963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.